CHARACTERIZATION OF A FRAME-SHIFT MUTATION IN CLINICAL ISOLATES OF MYCOBACTERIUM TUBERCULOSIS RV1738, A KEY GENE ENABLING DORMANCY AND PERSISTENT LATENCY

Paul Freidlin Israel Nissan Hasia Kaidar-Shwartz Zeev Dveyrin Efrat Rorman
National Public Health Laboratory Tel Aviv, Ministry of Health, Tel Aviv

We used next generation sequencing to characterize clinical isolates of Mycobacterium tuberculosis (Mtb). Two clonal isolates from the same patient showed a frame-shift mutation in Mtb Rv1738. During hypoxic conditions Rv1738 is highly up-regulated by the DosR operon, Rv1738 becoming the most abundant protein in the cell. Rv1738 is a conserved small protein of 94 amino acids. Recently, the structure of this protein was determined and it revealed a surprising similarity to a family of stress proteins known as hibernation-promoting factors (HPFs) like E. coli YfiA. YfiA reversibly inhibit translation and protein synthesis by binding to a deep groove in the 30S ribosomal subunit. This suggests that the functional role of the up-regulated Rv1738 protein in non-replicating persistence of Mtb is to contribute to the shutdown of ribosomal protein synthesis.

The Rv1738 polypeptide is folded into a three-stranded antiparallel β-sheet packed against a long C-terminal amphipathic α-helix (residues 55–86). The protein forms an intimately associated homodimer in which the extended β-sheet wraps around the two antiparallel C-terminal α-helices, which pack against the β-sheet and make intimate side chain–side chain interactions with each other. The frame shift in codon 73 of Rv1738 with the introduction of a wrong amino acid and creation of a 100 amino acid long mutant protein, causes a severe disruption in the alpha helix and possibly may affect dimerization and binding to the ribosome. A significant question that needs answering is about the ability of these mutants to hibernate. A structural homology search revealed an additional 12 GenBank entries with identical Rv1738 frame shift insertions, making this a rare but potentially successful evolutionary strategy of unknown significance.

Paul Freidlin
Paul Freidlin
Ministry of Health, National Public Health Laboratory Tel Aviv








Powered by Eventact EMS